Drug intelligence / Profile preview

BRE-MI01

Development stage: Preclinical
Lead developer: Brexogen
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

BRE-MI01 is an exosome-based therapeutic candidate developed by Brexogen for the treatment of myocardial infarction. Utilizing the proprietary BG-Platform, the drug consists of exosomes (BxC-R11e) derived from tissue regeneration-enhanced stem cells (BxC-R11) that have been primed with a specific compound to enhance their cardioprotective properties. As a cell-free regenerative medicine, BRE-MI01 is designed to deliver therapeutic cargo to the heart to promote tissue repair and recovery following an ischemic event. It is currently in preclinical development, with plans to enter clinical trials in the United States.

Other names: BxC-R11eBxC-R-11eBxC-R 11e

Beyond the preview

Go deeper on BRE-MI01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRE-MI01.

Explore the full profile